From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Journal: Journal Of Clinical Medicine
Published:
Abstract

Head and neck squamous cell carcinoma (HNSCC) is diagnosed in more than 71,000 patients each year in the United States, with nearly 16,000 associated deaths. One significant hurdle in the treatment of HNSCC is acquired and intrinsic resistance to existing therapeutic agents. Over the past several decades, the University of Wisconsin has formed a multidisciplinary team to move basic scientific discovery along the translational spectrum to impact the lives of HNSCC patients. In this review, we outline key discoveries made throughout the years at the University of Wisconsin to deepen our understanding of therapeutic resistance in HNSCC and how a strong, interdisciplinary team can make significant advances toward improving the lives of these patients by combatting resistance to established therapeutic modalities. We are profoundly grateful to the many scientific teams worldwide whose groundbreaking discoveries, alongside evolving clinical paradigms in head and neck oncology, have been instrumental in making our work possible.

Authors
Bridget Crossman, Regan Harmon, Kourtney Kostecki, Nellie Mcdaniel, Mari Iida, Luke Corday, Christine Glitchev, Madisen Crow, Madelyn Harris, Candie Lin, Jillian Adams, Colin Longhurst, Kwangok Nickel, Irene Ong, Roxana Alexandridis, Menggang Yu, David Yang, Rong Hu, Zachary Morris, Gregory Hartig, Tiffany Glazer, Sravani Ramisetty, Prakash Kulkarni, Ravi Salgia, Randall Kimple, Justine Bruce, Paul Harari, Deric Wheeler